US pharmaceutical company AMRI opened its research center in Budapest, the company announced.
The successful completion and move into 32,300 square feet (3,000 square meters) of laboratory and administrative space marks a significant milestone in the company’s plan initiated in 2008 to transform its European hub into a higher value discovery services business through consolidation of multiple locations, equipment and operating costs, AMRI said in a press release.
In addition to the significant improvements in operational efficiencies and enhanced technology transfer, the new site provides capacity for the anticipated expansion of synthetic chemistry services, currently projected to double over the next five years.
Figuring prominently in the mix of services will be expanded offerings in parallel synthesis and medicinal chemistry, and the establishment of fragment-based drug discovery. The facility also includes a scale-up laboratory for non GMP synthesis for batch sizes up to 25 liters.
“The successful completion of this expansion increases the ability of AMRI to execute on its strategy to accelerate growth and expand its presence in the European marketplace,” said Chairman, CEO and President Thomas E. D’Ambra, Ph.D. “Critical to the decision to undertake this project was the company’s drive to cultivate a customer base relatively untapped. We believe this latest investment, along with our parallel investments in the US, India and Singapore, will further strengthen AMRI’s presence as a premier provider of a broad range of scientific services, capabilities and geographic choices around the globe.” (press release)